|
Therapeutic Targets
The Company has identified beneficial effects of its lead product, MC-1, on certain cardiovascular and metabolic indications. Subsequent products developed through the Drug
Discovery Program, have potential applications in thrombosis. Medicure remains committed and
enthusiastic about developing new drugs and novel treatments for improving
outcomes of victims of various cardiovascular diseases.
Thrombosis
Hypertension
Diabetes
Metabolic Syndrome
Additional information can be found
at the following Web sites:
American Heart Association
Heart & Stroke Fondation of Canada
American Diabetes Association
Canadian Diabetes Association
American College of Cardiology
Health Canada
|
|
Management Team 
